Industry Newsmultiple myelomabcmajnjregulatory approval
Johnson & Johnson Receives FDA Approval For Myeloma
7.1
Johnson & Johnson on March 5 said the FDA approved TECVAYLI plus DARZALEX FASPRO for adults with relapsed or refractory multiple myeloma after at least one prior therapy, including a proteasome inhibitor and an immunomodulatory agent. Management said the combination could become a second-line standard for about 40% of relapsing patients by targeting BCMA-expressing cells. JPMorgan also raised JNJ's price target to $250 from $225, keeping a Neutral rating.
Key Points
- 1Announces FDA approval of TECVAYLI plus DARZALEX FASPRO for relapsed or refractory multiple myeloma.
- 2Highlights potential second-line standard for roughly 40% of patients by targeting BCMA-expressing cells.
- 3Affects commercial outlook and investment view; JPMorgan raises JNJ price target to $250.
Scoring Rationale
High clinical and commercial significance with official FDA approval, limited DS relevance outside biotech investing.
Practice interview problems based on real data
1,625 SQL & Python problems across 15 industry datasets — the exact type of data you work with.
Try 250 free problems
